| Code | CSB-RA004847MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Denikitug, targeting the C-C chemokine receptor type 8 (CCR8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and type 2 helper T cells. CCR8 plays a critical role in immune regulation by mediating chemotaxis in response to its ligands CCL1 and CCL18, directing T cell migration to inflammatory sites and the tumor microenvironment. The receptor is particularly significant in cancer immunology, as CCR8-positive Tregs are enriched in various solid tumors where they suppress anti-tumor immune responses, making CCR8 an attractive target for cancer immunotherapy.
Denikitug is a humanized IgG1 monoclonal antibody designed to selectively deplete CCR8-positive Tregs within tumors while sparing peripheral Tregs, potentially enhancing anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating CCR8 biology, Treg function in tumor immunity, and immune checkpoint mechanisms. It supports studies exploring novel immunotherapeutic strategies and understanding the role of chemokine receptors in immune cell trafficking and tumor immune evasion.
There are currently no reviews for this product.